Related references
Note: Only part of the references are listed.Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes
Oyepeju Ogundipe et al.
ACTA DIABETOLOGICA (2021)
Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors
Kristin Engelhardt et al.
ANNALS OF PHARMACOTHERAPY (2021)
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction The EMPEROR-Reduced Trial
Milton Packer et al.
CIRCULATION (2021)
Renal function and attributable risk of death and cardiovascular hospitalization in participants with diabetes from a registry-based cohort
Manuel Ruiz-Quintero et al.
PRIMARY CARE DIABETES (2021)
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Juan P. Frias et al.
DIABETES CARE (2021)
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
Thomas Karagiannis et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae-Seung Yun et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis
Jane L. Tarry-Adkins et al.
DIABETES THERAPY (2021)
Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies
Yanbo Zhang et al.
DIABETOLOGIA (2020)
Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo
Pierre Ambrosi et al.
CARDIOLOGY (2020)
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
W. Timothy Garvey et al.
DIABETES CARE (2020)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
Adherence to healthy lifestyles and incidence of diabetes and mortality among individuals with diabetes: a systematic review and meta-analysis of prospective studies
Sabrina Schlesinger et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2020)
ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk
Hongmei Zhang et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Tina K. Thethi et al.
DIABETES OBESITY & METABOLISM (2020)
Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials
Dario Giugliano et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Virtually Perfect? Telemedicine for Covid-19
Judd E. Hollander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
Besmir Nreu et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Five principles for pandemic preparedness: lessons from the Australian COVID-19 primary care response
Michael R. Kidd
BRITISH JOURNAL OF GENERAL PRACTICE (2020)
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
Ian H. de Boer et al.
KIDNEY INTERNATIONAL (2020)
Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials
Dimitris Varvaki Rados et al.
SCIENTIFIC REPORTS (2020)
The influence of hemoglobin A1c levels on cardiovascular events and all-cause mortality in people with diabetes over 70 years of age. A prospective study
Domingo Orozco-Beltran et al.
PRIMARY CARE DIABETES (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
Olesya M. Taylor et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2020)
The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now
Michael E. Johansen et al.
CLINICAL CARDIOLOGY (2020)
Role of social and other determinants of health in the effect of a multicomponent integrated care strategy on type 2 diabetes mellitus
Ruben Silva-Tinoco et al.
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH (2020)
Elevated mortality of chronic diseases during COVID-19 pandemic: a cause for concern?
Yang Xia et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2020)
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)
Neda Laiteerapong et al.
DIABETES CARE (2019)
Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes
Kamlesh Khunti et al.
DIABETES CARE (2019)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2019 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2019)
Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people A position statement of Primary Care Diabetes Europe
C. E. Hambling et al.
PRIMARY CARE DIABETES (2019)
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
Dan Liu et al.
BMC PHARMACOLOGY & TOXICOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis
D. Giugliano et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)
Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes
Iliana C. Lega et al.
DIABETES OBESITY & METABOLISM (2019)
Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK
S. C. Bain et al.
DIABETIC MEDICINE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Intensive Glucose Control in Patients with Type 2 Diabetes-15-Year Follow-up
Peter D. Reaven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects
Lance A. Sloan
JOURNAL OF DIABETES (2019)
Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes
Fernando Alvarez-Guisasola et al.
ATENCION PRIMARIA (2019)
Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial
Tamar de Vries et al.
DIABETES CARE (2019)
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
Michael A. Nauck et al.
DIABETES CARE (2019)
The right place for Sulphonylureas today: Part of 'Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus'
David R. Webb et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status
Craig J. Currie et al.
PLOS ONE (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study
Claire A. Lawson et al.
LANCET PUBLIC HEALTH (2019)
Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables
Tricia Santos Cavaiola et al.
CLINICAL THERAPEUTICS (2019)
Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019
William T. Cefalu et al.
DIABETES CARE (2019)
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
Kare I. Birkeland et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease
Donald M. Lloyd-Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera et al.
DIABETES THERAPY (2019)
Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial
Simon J. Griffin et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
Sachin Khunti et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2019)
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017
Thomas R. Einarson et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Karin Radholm et al.
CIRCULATION (2018)
Implementation of a Structured Diabetes Consultation Model to Facilitate a Person-Centered Approach: Results From a Nationwide Dutch Study
Guy E. H. M. Rutten et al.
DIABETES CARE (2018)
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Liana K. Billings et al.
DIABETES CARE (2018)
A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study
Robert Ritzel et al.
DIABETES CARE (2018)
Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials
Chi-Jung Huang et al.
DIABETES OBESITY & METABOLISM (2018)
Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial
Martin Ridderstrale et al.
DIABETES OBESITY & METABOLISM (2018)
The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
Stephen Colagiuri et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis
Kamlesh Khunti et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Diabetes research in primary care: fiction, reality or essential?
K. Khunti et al.
DIABETIC MEDICINE (2018)
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
Franco Cosmi et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Does lower limb amputation concern all SGLT2 inhibitors?
Andre J. Scheen
NATURE REVIEWS ENDOCRINOLOGY (2018)
Management of diabetes in older adults
G. Sesti et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2018)
Secondary Prevention of Cardiovascular Diseases and Application of Technology for Early Diagnosis
Sachith Paramie Karunathilake et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
Emma Ahlqvist et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population
Claire A. Lawson et al.
JACC-HEART FAILURE (2018)
Worsening Heart Failure During the Use of DPP-4 Inhibitors Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications
Milton Packer
JACC-HEART FAILURE (2018)
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
James B. Young et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study
Clara K. Chow et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study
Gyorgy Jermendy et al.
DIABETES THERAPY (2018)
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
DIABETES CARE (2018)
12. Older Adults: Standards of Medical Care in Diabetes—2019
DIABETES CARE (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacy
Thomas M. Polasek et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2018)
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2018)
Treatment approach to type 2 diabetes: Past, present and future
Kristina Blaslov et al.
WORLD JOURNAL OF DIABETES (2018)
The treatment of type 2 diabetes in heart failure
Andrea Llano et al.
PRACTICAL DIABETES (2018)
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum
William T. Cefalu et al.
DIABETES CARE (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Utilization of registered nurses in primary care teams: A systematic review
Allison Norful et al.
INTERNATIONAL JOURNAL OF NURSING STUDIES (2017)
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes The SWITCH 2 Randomized Clinical Trial
Carol Wysham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999-2010
Nana Zhang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2017)
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Jonathan D. Newman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Health Effects of Overweight and Obesity in 195 Countries over 25 Years
Ashkan Afshin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
Kelly R. Burke et al.
PHARMACOTHERAPY (2017)
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
Mohsen Mazidi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Ahren et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial
Aaron Baum et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Rury R. Holman et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Andrew McGovern et al.
DIABETES THERAPY (2017)
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Andrew McGovern et al.
DIABETES THERAPY (2017)
Diabetic Kidney Disease Challenges, Progress, and Possibilities
Radica Z. Alicic et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?
Laurentiu M. Pop et al.
CURRENT DIABETES REPORTS (2017)
Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis
Kamlesh Khunti et al.
DIABETES CARE (2017)
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
Marit de Jong et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Simon J. Griffin et al.
DIABETOLOGIA (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Diabetes Mellitus and Heart Failure
Michael Lehrke et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis
Stig Ejdrup Andersen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review
Bruno Rushforth et al.
BRITISH JOURNAL OF GENERAL PRACTICE (2016)
Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity
Faidon Magkos et al.
CELL METABOLISM (2016)
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
Vanita R. Aroda et al.
DIABETES CARE (2016)
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Francesco Giorgino et al.
DIABETES CARE (2016)
Hypoglycemia and Cardiovascular Risk: Is There a Major Link?
Markolf Hanefeld et al.
DIABETES CARE (2016)
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
Muh Geot Wong et al.
DIABETES CARE (2016)
Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme
M. Yu et al.
DIABETES OBESITY & METABOLISM (2016)
Where frailty meets diabetes
Stany Perkisas et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Polypharmacy in the Aging Patient A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Kasia J. Lipska et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers
John E. Anderson et al.
POSTGRADUATE MEDICINE (2016)
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
William H. Polonsky et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
The changing face of diabetes complications
Edward W. Gregg et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Sulfonylureas and their use in clinical practice
Daniele Sola et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes
Kristy Iglay et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Luc Van Gaal et al.
DIABETES CARE (2015)
Evidence Tips the Scale Toward Screening for Hyperglycemia
K. M. Venkat Narayan et al.
DIABETES CARE (2015)
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial
M. A. Abdul-Ghani et al.
DIABETES OBESITY & METABOLISM (2015)
Prediction of heart failure in patients with type 2 diabetes mellitus-A systematic review and meta-analysis
Ying Wang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
Feng Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Andy Menke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies
Chloe L. Edridge et al.
PLOS ONE (2015)
Sarcopenia and diabetes: Hyperglycemia is a risk factor for age-associated muscle mass and functional reduction
Hiroyuki Umegaki
JOURNAL OF DIABETES INVESTIGATION (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes
James J. DiNicolantonio et al.
OPEN HEART (2015)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Matthew C. Riddle et al.
DIABETES CARE (2014)
Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: Data from the Adult Diabetes Control and Management
Shariff-Ghazali Sazlina et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2014)
Diabetes treatment in patients with renal disease: Is the landscape clear enough?
Ioannis Ioannidis
WORLD JOURNAL OF DIABETES (2014)
The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
Rodolfo Guardado-Mendoza et al.
ARCHIVES OF MEDICAL SCIENCE (2013)
Generalist solutions to complex problems: generating practice-based evidence - the example of managing multi-morbidity
Joanne Reeve et al.
BMC FAMILY PRACTICE (2013)
Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic Meta-analysis
Qibo Zhu et al.
CLINICAL THERAPEUTICS (2013)
Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden
Mark Corriere et al.
CURRENT DIABETES REPORTS (2013)
Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology
Richard M. Cubbon et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Quality of Care of People With Type 2 Diabetes in Eight European Countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study
Margaret A. Stone et al.
DIABETES CARE (2013)
Obesity Paradox Does Exist
Vojtech Hainer et al.
DIABETES CARE (2013)
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
M. Nauck et al.
DIABETES OBESITY & METABOLISM (2013)
External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?
C. Saunders et al.
DIABETIC MEDICINE (2013)
Age ≥ 60 years was an independent risk factor for diabetes-related complications despite good control of cardiovascular risk factors in patients with type 2 diabetes mellitus
Boon How Chew et al.
EXPERIMENTAL GERONTOLOGY (2013)
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Vlado Perkovic et al.
KIDNEY INTERNATIONAL (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Postprandial blood glucose is associated with generalized pruritus in patients with type 2 diabetes
Mei-Ju Ko et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2013)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Metformin therapy in patients with chronic kidney disease
J. K. Duong et al.
DIABETES OBESITY & METABOLISM (2012)
What causes the insulin resistance underlying obesity?
Olga T. Hardy et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2012)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Thiazolidinediones and fracture risk in patients with Type 2 diabetes
D. J. Betteridge
DIABETIC MEDICINE (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Tina Ken Schramm et al.
EUROPEAN HEART JOURNAL (2011)
Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial
Simon J. Griffin et al.
LANCET (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The Effect of Oral Antidiabetic Agents on A1C Levels
Diana Sherifali et al.
DIABETES CARE (2010)
Pioglitazone: side effect and safety profile
Priya Shah et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull et al.
DIABETOLOGIA (2009)
Clinical inertia in general practice: widespread and related to the outcome of diabetes care
Rykel van Bruggen et al.
FAMILY PRACTICE (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Refill adherence and polypharmacy among patients with type 2 diabetes in general practice
Rykel van Bruggen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
The Metabolic Syndrome
Marc-Andre Cornier et al.
ENDOCRINE REVIEWS (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Kjeld Hermansen et al.
DIABETES CARE (2006)
Patients with poorly controlled diabetes in primary care: healthcare clinicians' beliefs and attitudes
D Jeavons et al.
POSTGRADUATE MEDICAL JOURNAL (2006)
Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes
SM Haffner
EUROPEAN HEART JOURNAL SUPPLEMENTS (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
B Charbonnel et al.
DIABETOLOGIA (2005)
The pathobiology of diabetic complications - A unifying mechanism
M Brownlee
DIABETES (2005)
Contribution of primary care to health systems and health
B Starfield et al.
MILBANK QUARTERLY (2005)
alpha-Glucosidase inhibitors for patients with type 2 diabetes - Results from a cochrane systematic review and meta-analysis
FA van de Laar et al.
DIABETES CARE (2005)
Blood pressure and stroke - An overview of published reviews
CMM Lawes et al.
STROKE (2004)
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus:: A double-blind, randomized trial
G Schernthaner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure
RW Nesto et al.
DIABETES CARE (2004)
Effect of thiazolidinediones on body weight in patients with diabetes mellitus
V Fonseca
AMERICAN JOURNAL OF MEDICINE (2003)
Thiazolidinediones and blood lipids in type 2 diabetes
JPH van Wijk et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
JL Chiasson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Improving glycaemic control in patients with Type 2 diabetes mellitus without insulin therapy
AN Goudswaard et al.
DIABETIC MEDICINE (2003)
Complications in young adults with early-onset type 2 diabetes - Losing the relative protection of youth
TA Hillier et al.
DIABETES CARE (2003)
Improving primary care for patients with chronic illness - The chronic care model, part 2
T Bodenheimer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Metformin: An update
D Kirpichnikov et al.
ANNALS OF INTERNAL MEDICINE (2002)
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
P Raskin et al.
DIABETES CARE (2001)
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 1 diabetes
H Yki-Järvinen et al.
DIABETES CARE (2000)
Share Paper
